NCT05142241View on ClinicalTrials.gov

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

September 26, 2025

Study Completion Date

September 29, 2026

Conditions
Adrenal Gland PheochromocytomaHematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmParaganglioma
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Talazoparib

Given PO

DRUG

Temozolomide

Given PO

Trial Locations (2)

20892

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH